Skip to main content
SpringerLink
Log in

BMSC-derived Exosomes Ameliorate Peritoneal Dialysis-associated Peritoneal Fibrosis via the Mir-27a-3p/TP53 Pathway

  • Original Article
  • Published:
Current Medical Science Aims and scope Submit manuscript

Abstract

Objective

Peritoneal fibrosis (PF) is the main cause of declining efficiency and ultrafiltration failure of the peritoneum, which restricts the long-term application of peritoneal dialysis (PD). This study aimed to investigate the therapeutic effects and mechanisms of bone marrow mesenchymal stem cells-derived exosomes (BMSC-Exos) on PF in response to PD.

Methods

Small RNA sequencing analysis of BMSC-Exos was performed by second-generation sequencing. C57BL/6J mice were infused with 4.25% glucose-based peritoneal dialysis fluid (PDF) for 6 consecutive weeks to establish a PF model. A total of 36 mice were randomly divided into 6 groups: control group, 1.5% PDF group, 2.5% PDF group, 4.25% PDF group, BMSC-Exos treatment group, and BMSC-Exos+TP53 treatment group. Reverse transcription quantitative polymerase chain reaction (RT-qPCR) was performed to measure the expression level of miR-27a-3p in BMSC-Exos and peritoneum of mice treated with different concentrations of PDF. HE and Masson staining were performed to evaluate the extent of PF. The therapeutic potential of BMSC-Exos for PF was examined through pathological examination, RT-qPCR, Western blotting, and peritoneal function analyses. Epithelial-mesenchymal transition (EMT) of HMrSV5 was induced with 4.25% PDF. Cells were divided into control group, 4.25% PDF group, BMSC-Exos treatment group, and BMSC-Exos+TP53 treatment group. Cell Counting Kit-8 assay was used to measure cell viability, and transwell migration assay was used to verify the capacity of BMSC-Exos to inhibit EMT in HMrSV5 cells.

Results

Small RNA sequencing analysis showed that miR-27a-3p was highly expressed in BMSC-derived exosomes compared to BMSCs. The RT-qPCR results showed that the expression of miR-27a-3p was upregulated in BMSC-Exos, but decreased in PD mice. We found that PF was glucose concentration-dependently enhanced in the peritoneum of the PD mice. Compared with the control mice, the PD mice showed high solute transport and decreased ultrafiltration volume as well as an obvious fibroproliferative response, with markedly increased peritoneal thickness and higher expression of α-SMA, collagen-I, fibronectin, and ECM1. The mice with PD showed decreased miR-27a-3p. Peritoneal structural and functional damage was significantly attenuated after BMSC-Exos treatment, while PF and mesothelial damage were significantly ameliorated. Additionally, markers of fibrosis (α-SMA, collagen-I, fibronectin, ECM1) and profibrotic cytokines (TGF-β1, PDGF) were downregulated at the mRNA and protein levels after BMSC-Exos treatment. In HMrSV5 cells, BMSC-Exos reversed the decrease in cell viability and the increase in cell migratory capacity caused by high-glucose PDF. Western blotting and RT-qPCR analysis revealed that BMSC-Exos treatment resulted in increased expression of E-cadherin (epithelial marker) and decreased expression of α-SMA, Snail, and vimentin (mesenchymal markers) compared to those of the 4.25% PDF-treated cells. Importantly, a dual-luciferase reporter assay showed that TP53 was a target gene of miR-27a-3p. TP53 overexpression significantly reversed the decreases in PF and EMT progression induced by BMSC-Exos.

Conclusion

The present results demonstrate that BMSC-Exos showed an obvious protective effect on PD-related PF and suggest that BMSC-derived exosomal miR-27a-3p may exert its inhibitory effect on PF and EMT progression by targeting TP53.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Liyanage T, Ninomiya T, Jha V, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet, 2015,385(9981):1975–1982

    Article  PubMed  Google Scholar 

  2. Cho Y, Bello AK, Levin A, et al. Peritoneal Dialysis Use and Practice Patterns: An International Survey Study. Am J Kidney Dis, 2021,77(3):315–325

    Article  PubMed  Google Scholar 

  3. Holmes CJ, Faict D. Peritoneal dialysis solution biocompatibility: definitions and evaluation strategies. Kidney Int Suppl, 2003,(88):S50-S56

  4. Krediet RT, Struijk DG. Peritoneal changes in patients on long-term peritoneal dialysis. Nat Rev Nephrol, 2013,9(7):419–429

    Article  CAS  PubMed  Google Scholar 

  5. Teitelbaum I. Ultrafiltration failure in peritoneal dialysis: a pathophysiologic approach. Blood Purif, 2015,39(1–3):70–73

    Article  CAS  PubMed  Google Scholar 

  6. Jagirdar RM, Bozikas A, Zarogiannis SG, et al. Encapsulating Peritoneal Sclerosis: Pathophysiology and Current Treatment Options. Int J Mol Sci, 2019,20(22):5765

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Fan YP, Hsia CC, Tseng KW, et al. The Therapeutic Potential of Human Umbilical Mesenchymal Stem Cells From Wharton’s Jelly in the Treatment of Rat Peritoneal Dialysis-Induced Fibrosis. Stem Cells Transl Med, 2016,5(2):235–247

    Article  CAS  PubMed  Google Scholar 

  8. Ueno T, Nakashima A, Doi S, et al. Mesenchymal stem cells ameliorate experimental peritoneal fibrosis by suppressing inflammation and inhibiting TGF-beta1 signaling. Kidney Int, 2013,84(2):297–307

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Nagasaki K, Nakashima A, Tamura R, et al. Mesenchymal stem cells cultured in serum-free medium ameliorate experimental peritoneal fibrosis. Stem Cell Res Ther, 2021,12(1):203

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Wang J, Wang L, Xu L, et al. Targeting Src attenuates peritoneal fibrosis and inhibits the epithelial to mesenchymal transition. Oncotarget, 2017,8(48):83872–83889

    Article  PubMed  PubMed Central  Google Scholar 

  11. Morishita Y, Ookawara S, Hirahara I, et al. HIF-1alpha mediates Hypoxia-induced epithelial-mesenchymal transition in peritoneal mesothelial cells. Ren Fail, 2016,38(2):282–289

    Article  CAS  PubMed  Google Scholar 

  12. Chen JS, Wong VW, Gurtner GC. Therapeutic potential of bone marrow-derived mesenchymal stem cells for cutaneous wound healing. Front Immunol, 2012,3:192

    Article  PubMed  PubMed Central  Google Scholar 

  13. Han Y, Li X, Zhang Y, et al. Mesenchymal Stem Cells for Regenerative Medicine. Cells, 2019,8(8):886

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Nagaishi K, Mizue Y, Chikenji T, et al. Mesenchymal stem cell therapy ameliorates diabetic nephropathy via the paracrine effect of renal trophic factors including exosomes. Sci Rep, 2016,6:34842

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Li M, Li S, Du C, et al. Exosomes from different cells: Characteristics, modifications, and therapeutic applications. Eur J Med Chem, 2020,207:112784

    Article  CAS  PubMed  Google Scholar 

  16. Murray L, Krasnodembskaya AD. Concise Review: Intercellular Communication Via Organelle Transfer in the Biology and Therapeutic Applications of Stem Cells. Stem Cells, 2019,37(1):14–25

    Article  PubMed  Google Scholar 

  17. Fan C, Wang Q, Chen Y, et al. Exosomes derived from bone mesenchymal stem cells attenuate myocardial fibrosis both in vivo and in vitro via autophagy activation: the key role of miR-199a-3p/mTOR pathway. Hum Cell, 2022,35(3):817–835

    Article  CAS  PubMed  Google Scholar 

  18. Ma J, Li Y, Chen M, et al. hMSCs-derived exosome circCDK13 inhibits liver fibrosis by regulating the expression of MFGE8 through miR-17-5p/KAT2B. Cell Biol Toxicol, 2023,39(2):1–22

    Article  CAS  PubMed  Google Scholar 

  19. Sun C, Shi C, Duan X, et al. Exosomal microRNA-618 derived from mesenchymal stem cells attenuate the progression of hepatic fibrosis by targeting Smad4. Bioengineered, 2022,13(3):5915–5927

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Xu L, Fan Y, Wu L, et al. Exosomes from Bone Marrow Mesenchymal Stem Cells with Overexpressed Nrf2 Inhibit Cardiac Fibrosis in Rats with Atrial Fibrillation. Cardiovasc Ther, 2022,2022:2687807

    Article  PubMed  PubMed Central  Google Scholar 

  21. Yao L, Ye Y, Mao H, et al. MicroRNA-124 regulates the expression of MEKK3 in the inflammatory pathogenesis of Parkinson’s disease. J Neuroinflammation, 2018,15(1):13

    Article  PubMed  PubMed Central  Google Scholar 

  22. Hu J, Shan Z, Hu K, et al. miRNA-223 inhibits epithelial-mesenchymal transition in gastric carcinoma cells via Sp1. Int J Oncol, 2016,49(1):325–335

    Article  CAS  PubMed  Google Scholar 

  23. Jaca A, Govender P, Locketz M, et al. The role of miRNA-21 and epithelial mesenchymal transition (EMT) process in colorectal cancer. J Clin Pathol, 2017,70(4):331–356

    Article  CAS  PubMed  Google Scholar 

  24. Domingues C, Serambeque BP, Laranjo CM, et al. Epithelial-mesenchymal transition and microRNAs: Challenges and future perspectives in oral cancer. Head Neck, 2018,40(10):2304–2313.

    Article  PubMed  Google Scholar 

  25. Lin F, Wu X, Zhang H, et al. A microrna screen to identify regulators of peritoneal fibrosis in a rat model of peritoneal dialysis. BMC Nephrol, 2015,16:48

    Article  PubMed  PubMed Central  Google Scholar 

  26. Li X, Liu H, Sun L, et al. MicroRNA-302c modulates peritoneal dialysis-associated fibrosis by targeting connective tissue growth factor. J Cell Mol Med, 2019,23(4):2372–2383

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Szeto CC, Chow KM, Kwan BC, et al. Peritoneal dialysis effluent miR-21 and miR-589 levels correlate with longitudinal change in peritoneal transport characteristics. Clin Chim Acta, 2017,464:106–112

    Article  CAS  PubMed  Google Scholar 

  28. Xi Y, Shen Y, Wu D, et al. CircBCAR3 accelerates esophageal cancer tumorigenesis and metastasis via sponging miR-27a-3p. Mol Cancer, 2022,21(1):145

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Guo D, Li Y, Chen Y, et al. DANCR promotes HCC progression and regulates EMT by sponging miR-27a-3p via ROCK1/LIMK1/COFILIN1 pathway. Cell Prolif, 2019,52(4):e12628

    Article  PubMed  PubMed Central  Google Scholar 

  30. Bello A K, Okpechi I G, Osman M A, et al. Epidemiology of peritoneal dialysis outcomes. Nat Rev Nephrol, 2022,18(12):779–793

    Article  PubMed  PubMed Central  Google Scholar 

  31. Gu C, Feng J, Waqas A, et al. Technological Advances of 3D Scaffold-Based Stem Cell/Exosome Therapy in Tissues and Organs. Front Cell Dev Biol, 2021,9:709204

    Article  PubMed  PubMed Central  Google Scholar 

  32. Fang Y, Garnier D, Lee TH, et al. PML-RARa modulates the vascular signature of extracellular vesicles released by acute promyelocytic leukemia cells. Angiogenesis, 2016,19(1):25–38

    Article  CAS  PubMed  Google Scholar 

  33. Vanherle S, Haidar M, Irobi J, et al. Extracellular vesicle-associated lipids in central nervous system disorders. Adv Drug Deliv Rev, 2020,159:322–331

    Article  CAS  PubMed  Google Scholar 

  34. Sabaratnam R, Geertsen L, Skjodt K, et al. In human nephrectomy specimens, the kidney level of tubular transport proteins does not correlate with their abundance in urinary extracellular vesicles. Am J Physiol Renal Physiol, 2019,317(3):F560–F571

    Article  CAS  PubMed  Google Scholar 

  35. Krediet R T. Ultrafiltration Failure Is a Reflection of Peritoneal Alterations in Patients Treated With Peritoneal Dialysis. Front Physiol, 2018,9:1815

    Article  PubMed  PubMed Central  Google Scholar 

  36. Yanai K, Ishii H, Aomatsu A, et al. MicroRNAs in peritoneal fibrosis: a systematic review. Discov Med, 2018,26(145):271–280

    PubMed  Google Scholar 

  37. Shin HS, Ko J, Kim DA, et al. Metformin ameliorates the Phenotype Transition of Peritoneal Mesothelial Cells and Peritoneal Fibrosis via a modulation of Oxidative Stress. Sci Rep, 2017,7(1):5690

    Article  PubMed  PubMed Central  Google Scholar 

  38. Ji S, Deng H, Jin W, et al. Beta-catenin participates in dialysate-induced peritoneal fibrosis via enhanced peritoneal cell epithelial-to-mesenchymal transition. FEBS Open Bio, 2017,7(2):265–273

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Sung SA, Kim DH, Oh KH, et al. The Role of Cathepsin B in Peritoneal Fibrosis due to Peritoneal Dialysis. Int J Nephrol, 2019,2019:4150656

    Article  PubMed  PubMed Central  Google Scholar 

  40. Yang A H, Chen JY, Lin JK. Myofibroblastic conversion of mesothelial cells. Kidney Int, 2003,63(4):1530–1539

    Article  PubMed  Google Scholar 

  41. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest, 2009,119(6):1420–1428

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Zhao JL, Guo MZ, Zhu JJ, et al. Curcumin suppresses epithelial-to-mesenchymal transition of peritoneal mesothelial cells (HMrSV5) through regulation of transforming growth factor-activated kinase 1 (TAK1). Cell Mol Biol Lett, 2019,24:32

    Article  PubMed  PubMed Central  Google Scholar 

  43. Haywood ME, Cocciolo A, Porter KF, et al. Transcriptome signature of ventricular arrhythmia in dilated cardiomyopathy reveals increased fibrosis and activated TP53. J Mol Cell Cardiol, 2020,139:124–134

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Author notes

  1. Both authors contributed equally to this study.

Authors and Affiliations

  1. Department of Nephrology, Shanghai University of Medicine & Health Sciences Affiliated Zhoupu Hospital, Shanghai, 201318, China

    Jun-li Zhao, Qiu-nan Zhan, Miao Liu, Ting Zhang & Wen-wen Chu

  2. Orthopedic Department, Guangming Traditional Chinese Medicine Hospital of Pudong New Area, Shanghai, 201399, China

    Lin Zhao

Authors
  1. Jun-li Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lin Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qiu-nan Zhan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Miao Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ting Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wen-wen Chu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jun-li Zhao.

Ethics declarations

The authors declare that there is no conflict of interest with any financial organization or corporation or individual that can inappropriately influence this work.

Additional information

This study was supported by the Technology Development Program of Shanghai Pudong New District (No. PKJ2021-Y34) and the Excellent Young Medical Talent Training Program of Pudong Health Commission of Shanghai (No. PWRq2022-18).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhao, Jl., Zhao, L., Zhan, Qn. et al. BMSC-derived Exosomes Ameliorate Peritoneal Dialysis-associated Peritoneal Fibrosis via the Mir-27a-3p/TP53 Pathway. CURR MED SCI 44, 333–345 (2024). https://doi.org/10.1007/s11596-024-2853-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11596-024-2853-7

Key words

Search

Navigation